GLP-1s + Finasteride: Hair, Libido, and the Unexpected Interaction

A 42-year-old has been on 1 mg finasteride for 12 years. Hairline stable. No side effects. He starts semaglutide for weight loss. Three months in, he notices his libido has dropped — not severely, but noticeably — and he's seeing more hair in the shower than usual. He assumes it's the GLP-1 causing both.

Probably not. The more likely story is that the GLP-1-driven weight loss is revealing something about his baseline that finasteride was partially masking — or that the temporary telogen effluvium that comes with any rapid weight loss is being misattributed to the medication stack.

The interaction between these two drugs is real but narrow. Here's what's actually happening, what to watch for, and when to pull either one.

What finasteride does (quick refresher)

Finasteride is a 5-alpha-reductase inhibitor. It blocks the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the primary androgen responsible for androgenetic alopecia (male pattern baldness) and prostatic hyperplasia. By reducing DHT by roughly 60–70%, finasteride halts or slows hair loss in most men who take it consistently.

Typical dosing:

• 1 mg daily for hair loss (Propecia, generic finasteride).
• 5 mg daily for benign prostatic hyperplasia (Proscar, generic).
• Topical finasteride (lotions, sprays) — newer, potentially lower systemic side effects.

Side effect profile at 1 mg is well-documented: approximately 1–4% of men report reduced libido, approximately 1–2% report erectile dysfunction, and a smaller percentage report post-finasteride syndrome symptoms that persist after discontinuation. The majority of men tolerate it without noticeable effects.

Interaction #1: Libido overlap

Both finasteride and GLP-1 therapy have modest potential effects on libido through different mechanisms:

• Finasteride — reduced DHT can blunt libido in a subset of men. Typically dose-dependent and often reversible with discontinuation.
• GLP-1 (early phase) — some men report reduced libido during the first 4–8 weeks of therapy, often associated with general fatigue and undernutrition during the titration phase. Usually resolves as the body adapts and weight loss drives testosterone recovery.

The net effect: if you were borderline symptomatic on finasteride alone, adding a GLP-1 may push you across the threshold temporarily. Not because of a true drug interaction, but because two modest signals summed are larger than either alone.

The fix isn't usually to stop either drug. The fix is to recognize that:

1. GLP-1-driven testosterone recovery (from fat loss) typically produces a net libido increase by month 6–9, which more than compensates for the finasteride effect.
2. If symptoms persist past month 6 on the stack, check hormone labs — the underlying picture may warrant adjustment.

Interaction #2: Telogen effluvium during rapid weight loss

This is the one most men misattribute. Rapid weight loss — including GLP-1-driven weight loss — commonly triggers telogen effluvium, a temporary form of shedding where a larger-than-normal proportion of hair follicles enter the shedding phase simultaneously. It typically begins 3–4 months after the weight loss starts and resolves 3–6 months after weight stabilizes.

The mechanism is not androgenic — it's a stress response driven by nutritional changes, hormonal shifts, and metabolic adjustment. Finasteride does not prevent telogen effluvium because finasteride addresses DHT-driven pattern loss, not stress-driven shedding.

The typical experience for men on both drugs during GLP-1 weight loss:

• Months 1–3: No hair changes beyond baseline.
• Months 4–6: Noticeable increased shedding, often panic-inducing. This is telogen effluvium.
• Months 7–12: Shedding normalizes. Hair density may actually be better than baseline because the metabolic improvement reverses some of the background stressors that were driving micro-inflammation at the follicle.

Don't stop finasteride. Don't stop the GLP-1. Don't add minoxidil in panic (though minoxidil is compatible and may help recovery). The shed is temporary.

Interaction #3: The testosterone recovery complicates DHT math

Here's where it gets interesting. GLP-1-driven weight loss tends to raise total testosterone significantly — the ENDO 2025 data showed 53% to 77% normalization over 18 months.¹ That rising testosterone means more substrate available for 5-alpha-reductase to convert to DHT.

For a man on finasteride, this means:

• DHT will stay suppressed as long as finasteride is taken consistently (the enzyme is blocked regardless of substrate).
• Free testosterone available for other androgen receptors (muscle, libido, mood) actually increases.
• Estradiol may rise with testosterone — relevant if you're watching for gyno or mood effects.

Net effect: the hair coverage benefit of finasteride is maintained, the libido/muscle benefit of rising testosterone is captured, and the main side effect (estradiol elevation) is manageable with monitoring. This is actually one of the better drug combinations in men's health — more androgen where you want it (muscle, libido, mood), same DHT suppression where you need it (scalp, prostate).

Should you reconsider finasteride on a GLP-1?

Generally no. The combination is not clinically problematic. But a few scenarios worth discussing with your prescriber:

• You were on finasteride because obesity-driven inflammation was accelerating pattern loss. Some of that inflammation resolves with weight loss — so a lower finasteride dose or a switch to topical may be adequate.
• You were borderline symptomatic. If libido or mood effects from finasteride were always a tension point, consider a switch to topical finasteride (0.1–0.25% solution), which achieves comparable hair preservation with 50–80% less systemic DHT reduction.
• You want to optimize testosterone recovery. Some providers consider temporarily pausing finasteride during the first 6 months of GLP-1 therapy to allow full testosterone and DHT recovery, then resuming as the weight stabilizes. This is a nuanced decision with tradeoffs.

Dutasteride vs. finasteride on a GLP-1

Dutasteride (Avodart) blocks both types 1 and 2 of 5-alpha-reductase, reducing DHT by approximately 90% versus finasteride's 60–70%. It's used off-label for hair loss in men who don't respond adequately to finasteride.

The interaction profile with GLP-1 is similar, but more pronounced:

• Deeper DHT suppression = higher rate of sexual side effects at baseline.
• Combined with GLP-1 early-phase libido blunting, the stack can feel more challenging in the first 3 months.
• Longer half-life of dutasteride (about 5 weeks) means washout if you discontinue takes months.

For men who are new to DHT inhibitors and also starting a GLP-1, finasteride is the safer first choice. Escalate to dutasteride only if finasteride proves inadequate after 12+ months of use.

The practical protocol

Hair-focused telehealth options

Several telehealth platforms offer finasteride (oral or topical), minoxidil, and other hair-loss treatments. If you're managing hair loss alongside a GLP-1 protocol, a specialized men's hair platform often has better prescribing nuance than a general GLP-1 provider.

The bottom line

Finasteride and GLP-1s are clinically compatible. The direct interaction is minimal. The indirect effects — libido overlap during titration, telogen effluvium during rapid weight loss, altered testosterone dynamics — are predictable and manageable.

If you're a long-time finasteride user starting a GLP-1: don't change the finasteride. Take photos. Expect a shed at month 3–4. Retest hormones at month 6. Make changes based on labs, not panic.

Most men end up better off on both drugs than on either alone: more muscle, recovered testosterone, preserved hair coverage, improved metabolic state. The 90-day adjustment period is rough. The 12-month outcome is worth it.